<div id="readability-page-1"><p>Bank of America Corp DE lessened its holdings in shares of  The Chemours Company (NYSE:CC - Free Report) by 62.8% in the fourth quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor  owned 166,649 shares of the specialty chemicals company's stock after selling 281,888 shares during the quarter. Bank of America Corp DE owned 0.11% of Chemours worth $2,816,000 at the end of the most recent quarter.</p><ul><li>Trump Orders Nuclear Overhaul: These 3 Stocks Stand to Benefit</li></ul><p>A number of other hedge funds have also recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its holdings in shares of  Chemours by 11.2% in the 4th quarter. BNP Paribas Financial Markets now owns 14,688 shares of the specialty chemicals company's stock worth $248,000 after purchasing an additional 1,481 shares during the last quarter.  Ameriprise Financial Inc. lifted its holdings in shares of  Chemours by 23.8% in the 4th quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock worth $73,907,000 after purchasing an additional 839,849 shares during the last quarter.  Algert Global LLC bought a new stake in  Chemours during the 4th quarter valued at $3,147,000.  Mercer Global Advisors Inc. ADV bought a new stake in  Chemours during the 4th quarter valued at $301,000.  Finally, Itau Unibanco Holding S.A. increased its position in shares of  Chemours by 39.3% during the 4th quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock valued at $60,000 after purchasing an additional 1,003 shares during the period. Institutional investors and hedge funds own  76.26% of the company's stock. </p><h2>Chemours Stock Performance</h2><p>Shares of NYSE CC opened at $10.15 on Friday. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of 17.81 and a beta of 1.76. The business has a fifty day simple moving average of $11.55 and a 200 day simple moving average of $15.65. The Chemours Company has a one year low of $9.33 and a one year high of $25.80. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70. </p><ul><li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li></ul><p>Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a net margin of 1.51% and a return on equity of 26.54%. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the prior year, the firm earned $0.32 earnings per share. The business's quarterly revenue was up .4% compared to the same quarter last year.  Sell-side analysts expect that  The Chemours Company will post 2.03 EPS for the current year. </p><h2>Chemours Announces Dividend</h2><p>The firm also recently declared a  dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be issued a $0.0875 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's dividend payout ratio  is 175.00%. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>3 AI ETFs Tapping Into the Heart of the AI Revolution</li></ul><p>Several equities analysts have recently issued reports on CC shares. BMO Capital Markets lowered their price target on Chemours from $34.00 to $27.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday, February 19th. Royal Bank of Canada lowered their target price on Chemours from $17.00 to $14.00 and set an &#34;outperform&#34; rating on the stock in a research note on Thursday, May 8th. Barclays lowered their target price on Chemours from $16.00 to $13.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Wednesday. Mizuho  set a $15.00 price target on Chemours in a research note on Tuesday, April 15th. Finally, Truist Financial lowered their target price on Chemours from $27.00 to $22.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, April 14th. One research analyst  has rated the stock with a sell rating, four have issued  a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $17.22.</p><p><b>Get Our Latest Analysis on CC</b></p><h2>Insider Activity at Chemours</h2><p>In other news, CFO Shane Hostetter acquired 4,450 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the completion of the transaction, the chief financial officer now directly owns 59,694 shares in the company, valued at $673,348.32. This trade represents a 8.06% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.34% of the stock is currently owned by company insiders. </p><h2>About Chemours</h2> (Free Report)<p>The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.</p><h2>See Also</h2><ul><li>Five stocks we like better than Chemours</li><li>Utilities Stocks Explained – How and Why to Invest in Utilities</li><li>Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look</li><li>Insider Trades May Not Tell You What You Think</li><li>3 Overlooked Dividend Plays for Income in Volatile Times</li><li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li><li>AXON: Competition Intensifies as Motorola Makes $4.4B Acquisition</li></ul><p><strong>Want to see what other hedge funds are holding CC?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUND?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUND"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Chemours Right Now?</h2><p>Before you consider Chemours, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.</p><p>While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Bank of America Corp DE reduced its stake in The Chemours Company (NYSE:CC) by 62.8% in Q4, now holding 166,649 shares valued at $2.8 million. Other investors, including BNP Paribas and Ameriprise Financial, increased their holdings. Chemours reported Q1 earnings of $0.13 EPS, missing estimates, with revenue of $1.37 billion. The company declared a dividend of $0.0875, yielding 3.17%. Analysts have mixed ratings, with a consensus target price of $17.22 and a "Hold" rating.</p>

The Chemours Company (NYSE:CC) Shares Sold by Bank of America Corp DE